☰

Anthony F. Shields - Publications

Affiliations: 
Cancer Biology Wayne State University, Detroit, MI, United States 
Area:
Oncology, Medical Biophysics
Tree Info Similar researchers PubMed Report error

227 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S, Zhang W, Millstein J, Johnston C, Goldberg RM, Philip PA, Seeber A, Xiu J, Hwang JJ, Shields AF, et al. Molecular characterization of appendiceal goblet cell carcinoid. Molecular Cancer Therapeutics. PMID 33037134 DOI: 10.1158/1535-7163.MCT-20-0318  0.333
2020 Lum LG, Thakur A, Choi M, Deol A, Kondadasula V, Schalk D, Fields K, Dufrense M, Philip P, Dyson G, Aon HD, Shields AF. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Oncoimmunology. 9: 1773201. PMID 32939319 DOI: 10.1080/2162402X.2020.1773201  0.362
2020 Sobrero AF, Puccini A, Shi Q, Grothey A, Andrè T, Shields AF, Souglakos I, Yoshino T, Iveson T, Ceppi M, Bruzzi P. A new prognostic and predictive tool for shared decision making in stage III colon cancer. European Journal of Cancer (Oxford, England : 1990). 138: 182-188. PMID 32892120 DOI: 10.1016/J.Ejca.2020.07.031  0.336
2020 Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, Shields AF, Xiu J, Battaglin F, Berger MD, Tokunaga R, Naseem M, Barzi A, Iqbal S, Zhang W, et al. Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32883742 DOI: 10.1158/1078-0432.Ccr-20-1804  0.305
2020 Zimmer K, Puccini A, Xiu J, Baca Y, Spizzo G, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, Kocher F, et al. -Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers. 12. PMID 32455893 DOI: 10.3390/Cancers12051319  0.373
2020 Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. Jnci Cancer Spectrum. 4: pkaa023. PMID 32455336 DOI: 10.1093/Jncics/Pkaa023  0.346
2020 Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability-high solid tumors. International Journal of Cancer. PMID 32449172 DOI: 10.1002/Ijc.33115  0.344
2020 Stein MK, Williard FW, Xiu J, Tsao MW, Martin MG, Deschner BW, Dickson PV, Glazer ES, Yakoub D, Shibata D, Grothey AF, Philip PA, Hwang JJ, Shields AF, Marshall JL, et al. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. Journal of Surgical Oncology. PMID 32166754 DOI: 10.1002/Jso.25899  0.374
2020 Coveler AL, Bajor DL, Masood A, Yilmaz E, Shields AF, Javle MM, Paluri RK, Vaccaro GM, Zalupski M, Grilley-Olson JE, Kindler HL, Schmitt MW, Gutierrez M. Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 38: TPS4671-TPS4671. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps4671  0.314
2020 Arora S, Xiu J, Sohal D, Lou E, Goldberg RM, Weinberg BA, Grothey A, Korn WM, Khushman M, Shields AF, Marshall J, Hall MJ. The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB). Journal of Clinical Oncology. 38: e13538-e13538. DOI: 10.1200/Jco.2020.38.15_Suppl.E13538  0.35
2020 Philip PA, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, Marshall J, Grothey A, Shields AF, Korn WM. Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC). Journal of Clinical Oncology. 38: 4629-4629. DOI: 10.1200/Jco.2020.38.15_Suppl.4629  0.358
2020 Battaglin F, Xiu J, Baca Y, Zeng J, Shields AF, Goldberg RM, Seeber A, Habib D, Puccini A, Tokunaga R, Arai H, Wang J, Berger MD, Astsaturov IA, Lockhart AC, et al. Comprehensive gene expression analysis of IDH1/2 mutant biliary cancers (BC). Journal of Clinical Oncology. 38: 4598-4598. DOI: 10.1200/Jco.2020.38.15_Suppl.4598  0.301
2020 Wang J, Xiu J, Shields AF, Grothey A, Weinberg BA, Marshall J, Lou E, Khushman MM, Sohal D, Hall MJ, Battaglin F, Arai H, Soni S, Zhang W, Korn WM, et al. Molecular correlates of PD-L1 expression in patients (pts) with gastroesophageal (GE) cancers. Journal of Clinical Oncology. 38: 4558-4558. DOI: 10.1200/Jco.2020.38.15_Suppl.4558  0.307
2020 Sobrero AF, Puccini A, Shi Q, Grothey A, Andre T, Shields AF, Ceppi M, Bruzzi P. A new prognostic and predictive tool to enhance shared decision making in stage III colon cancer. Journal of Clinical Oncology. 38: 4010-4010. DOI: 10.1200/Jco.2020.38.15_Suppl.4010  0.364
2020 Sobrero AF, Andre T, Meyerhardt JA, Grothey A, Iveson T, Yoshino T, Sougklakos I, Meyers JP, Labianca R, Saunders MP, Vernerey D, Yamanaka T, Boukovinas I, Oki E, Georgoulias V, ... ... Shields AF, et al. Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. Journal of Clinical Oncology. 38: 4004-4004. DOI: 10.1200/Jco.2020.38.15_Suppl.4004  0.352
2020 Meyerhardt JA, Shi Q, Fuchs CS, Niedzwiecki D, Zemla TJ, Kumthekar P, Guthrie KA, Couture F, Kuebler JP, Bendell JC, Kumar P, Lewis DA, Tan BR, Bertagnolli MM, Grothey A, ... ... Shields AF, et al. Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702. Journal of Clinical Oncology. 38: 4003-4003. DOI: 10.1200/Jco.2020.38.15_Suppl.4003  0.379
2020 Wang J, Xiu J, Shields AF, Grothey A, Weinberg BA, Marshall J, Lou E, Khushman MM, Sohal D, Hall MJ, Battaglin F, Arai H, Soni S, Zhang W, Korn WM, et al. Comprehensive molecular analysis of microsatellite-stable (MSS) tumors with high mutational burden in gastrointestinal (GI) cancers. Journal of Clinical Oncology. 38: 3631-3631. DOI: 10.1200/Jco.2020.38.15_Suppl.3631  0.317
2020 Chu QS, Jonker DJ, Provencher DM, Miller WH, Bouganim N, Shields AF, Shapiro G, Sawyer MB, Lheureux S, Samouelian V, Gotlieb WH, Esfahani K, Zaknoen SL, Smith PS, Owen J, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology. 38: 3581-3581. DOI: 10.1200/Jco.2020.38.15_Suppl.3581  0.353
2019 Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. Journal of Gastrointestinal Oncology. 10: 1099-1109. PMID 31949927 DOI: 10.21037/Jgo.2019.08.08  0.301
2019 Salem ME, Battaglin F, Goldberg RM, Puccini A, Shields AF, Arguello D, Korn WM, Marshall JL, Grothey A, Lenz HJ. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. The Oncologist. PMID 31848314 DOI: 10.1634/Theoncologist.2019-0552  0.354
2019 Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. Journal of Gastrointestinal Oncology. 10: 652-662. PMID 31392046 DOI: 10.21037/Jgo.2018.08.18  0.404
2019 El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca: a Cancer Journal For Clinicians. PMID 31116423 DOI: 10.3322/Caac.21560  0.311
2019 Feldmann DP, Jones S, Douglas K, Shields AF, Merkel OM. Microfluidic Assembly of siRNA-Loaded Micelleplexes for Tumor Targeting in an Orthotopic Model of Ovarian Cancer. Methods in Molecular Biology (Clifton, N.J.). 1974: 355-369. PMID 31099014 DOI: 10.1007/978-1-4939-9220-1_24  0.324
2019 Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801295. PMID 30817250 DOI: 10.1200/Jco.18.01295  0.384
2019 Ueberroth BE, Lawhorn-Crews JM, Heilbrun LK, Smith DW, Akoury J, Ali-Fehmi R, Eiseler NT, Shields AF. The use of 3'-deoxy-3'-F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy. Annals of Nuclear Medicine. PMID 30810980 DOI: 10.1007/S12149-019-01345-W  0.377
2019 Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, ... Shields AF, et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30692096 DOI: 10.1158/1078-0432.Ccr-18-3388  0.327
2019 Puccini A, Poorman K, Salem ME, Goldberg RM, Shields AF, Berger MD, Battaglin F, Tokunaga R, Naseem M, Zhang W, Soni S, Korn WM, Philip PA, Marshall J, Lenz H. Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon. Journal of Clinical Oncology. 37: 63-63. DOI: 10.1200/Jco.2019.37.4_Suppl.63  0.366
2019 Naseem M, Xiu J, Salem ME, Goldberg RM, Vanderwalde AM, Grothey A, Philip PA, Seeber A, Puccini A, Tokunaga R, Battaglin F, Berger MD, Barzi A, Hanna DL, Zhang W, ... ... Shields AF, et al. Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations. Journal of Clinical Oncology. 37: 606-606. DOI: 10.1200/Jco.2019.37.4_Suppl.606  0.334
2019 Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Hwang JJ, Marshall J, Vanderwalde AM, Shields AF, Lenz H, Salem ME, Philip PA, Goldberg RM, Korn WM, Kim SS. Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers. Journal of Clinical Oncology. 37: 60-60. DOI: 10.1200/Jco.2019.37.4_Suppl.60  0.324
2019 Hall MJ, Bodor JN, Xiu J, Feldman R, Grothey A, Goldberg RM, Worrilow WM, Hwang JJ, Kim ES, Lenz H, Raghavan D, Shields AF, Marshall J, Korn WM, Salem ME. Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs). Journal of Clinical Oncology. 37: 505-505. DOI: 10.1200/Jco.2019.37.4_Suppl.505  0.35
2019 Kamgar M, Dyson G, Shields AF, Tesfaye AA, Philip PA, Al Hallak MN. Comprehensive genomic profiling in metastatic pancreatic adenocarcinoma, correlation with early death versus prolonged survival. Journal of Clinical Oncology. 37: 282-282. DOI: 10.1200/Jco.2019.37.4_Suppl.282  0.326
2019 Lum LG, Le TM, Choi M, Thakur A, Reilley M, Kunk PR, Deol A, Ballen KK, Kindwall-Keller TL, Schalk D, Kubicka E, Huang M, Philip PA, Aoun H, Dyson G, ... ... Shields AF, et al. Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic pancreatic cancer. Journal of Clinical Oncology. 37: 4135-4135. DOI: 10.1200/Jco.2019.37.15_Suppl.4135  0.367
2019 Seeber A, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Philip PA, Marshall J, Kocher F, Hall MJ, Korn WM, et al. Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression. Journal of Clinical Oncology. 37: 4133-4133. DOI: 10.1200/Jco.2019.37.15_Suppl.4133  0.345
2019 Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman MM, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Philip PA, Hall MJ, Marshall J, et al. Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI). Journal of Clinical Oncology. 37: 4085-4085. DOI: 10.1200/Jco.2019.37.15_Suppl.4085  0.378
2019 Stein MK, Xiu J, Martin MG, Grothey A, Prouet P, Owsley J, Williard FW, Glazer ES, Dickson PV, Shibata D, Yakoub D, Goldberg RM, Korn WM, Shields AF, Hwang JJ, et al. Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer. Journal of Clinical Oncology. 37: 4053-4053. DOI: 10.1200/Jco.2019.37.15_Suppl.4053  0.332
2019 Seeber A, Kocher F, Xiu J, Spizzo G, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Naseem M, et al. Molecular landscape of colorectal cancers harboring R-spondin fusions. Journal of Clinical Oncology. 37: 3588-3588. DOI: 10.1200/Jco.2019.37.15_Suppl.3588  0.366
2019 Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Salem ME, Seeber A, Battaglin F, Berger MD, El-Deiry WS, Tokunaga R, Naseem M, Zhang W, Arora SP, Khushman MM, et al. Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC). Journal of Clinical Oncology. 37: 3130-3130. DOI: 10.1200/Jco.2019.37.15_Suppl.3130  0.359
2019 Salem M, Xiu J, Puccini A, Grothey A, Goldberg R, Hwang J, Gatalica Z, Feldman R, Saul M, Korn W, Hall M, El-Deiry W, Shields A, Marshall J, Lenz H, et al. Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas Annals of Oncology. 30: v787. DOI: 10.1093/Annonc/Mdz268.084  0.34
2019 Battaglin F, Xiu J, Baca Y, Goldberg RM, Grothey A, Shields AF, Seeber A, Salem ME, Puccini A, Tokunaga R, Naseem M, Arai H, Wang J, Berger MD, Zhang W, et al. Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz268.009  0.336
2019 Seeber A, Puccini A, Xiu J, Baca Y, Spizzo G, Zimmer K, Lenz HJ, Battaglin F, Goldberg RM, Grothey A, Shields AF, Salem ME, Marshall JL, Korn WM, Wolf D, et al. WRN mutated colorectal cancer (CRC) is characterized by a distinct molecular and immunological profile Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz246.122  0.357
2018 Salem M, Grothey A, Goldberg R, Xiu J, Korn W, Shields A, Hwang J, Philip P, Lenz H, Marshall J. Association between tumor mutation burden (TMB) and MLH1, PMS2, MSH2, and MSH6 alterations in 395 microsatellite instability-high (MSI-High) gastrointestinal (GI) tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v109. PMID 32177004 DOI: 10.1093/Annonc/Mdy149.024  0.307
2018 Puccini A, Poorman K, Goldberg R, Shields AF, Winerip M, Korn WM, Berger MD, Tokunaga R, Naseem M, Battaglin F, Zhang W, Soni S, Hwang JJ, Philip P, Marshall JL, et al. Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii649. PMID 32137763 DOI: 10.1093/Annonc/Mdy303.001  0.357
2018 Zhang KJ, Dyson G, Gatz JL, Silverman ME, Tesfaye AA, Shields AF, Philip PA. Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center. American Journal of Clinical Oncology. PMID 30601178 DOI: 10.1097/Coc.0000000000000507  0.406
2018 Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British Journal of Cancer. PMID 30361524 DOI: 10.1038/S41416-018-0235-2  0.331
2018 Vaishampayan U, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, Dobson KC, Boerner JL, Stark K, Smith D, Heath EI, Fontana J, Shields AF. Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30327304 DOI: 10.1158/1078-0432.Ccr-18-1473  0.31
2018 Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. The Oncologist. PMID 30018131 DOI: 10.1634/Theoncologist.2018-0117  0.377
2018 Jones SK, Douglas K, Shields AF, Merkel OM. Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model. Biomaterials. 178: 183-192. PMID 29935386 DOI: 10.1016/J.Biomaterials.2018.06.014  0.371
2018 Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. The Oncologist. PMID 29866946 DOI: 10.1634/Theoncologist.2018-0143  0.321
2018 Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. The Oncologist. PMID 29703766 DOI: 10.1634/Theoncologist.2018-0034  0.304
2018 McHugh C, Thipparthi MR, Lawhorn-Crews JM, Polin L, Gadgeel S, Akoury J, Mangner TJ, Douglas KA, Li J, Ratnam M, Shields AF. Utilizing radiolabeled 3'-deoxy-3'-[F]fluorothymidine with positron emission tomography to monitor the effect of dexamethasone on non-small cell lung cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29674424 DOI: 10.2967/Jnumed.117.207258  0.425
2018 Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. The New England Journal of Medicine. 378: 1177-1188. PMID 29590544 DOI: 10.1056/Nejmoa1713709  0.372
2018 Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR. Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 29563133 DOI: 10.1158/1055-9965.Epi-17-0769  0.375
2018 Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research : McR. PMID 29523759 DOI: 10.1158/1541-7786.Mcr-17-0735  0.365
2018 Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, Andre T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A. The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer? Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29438451 DOI: 10.1093/Annonc/Mdy064  0.406
2018 Abdallah N, Mohamed A, Ismail H, Chen W, Akhras A, Jang H, Smith DW, Tesfaye AA, Philip PA, Shields AF. Clinical outcome for continuous versus intermittent chemotherapy for unresectable metastatic colorectal cancer: Comparative analysis after first-line therapy. Journal of Clinical Oncology. 36: 825-825. DOI: 10.1200/Jco.2018.36.4_Suppl.825  0.402
2018 Mohamed A, Abdallah N, Ismail H, Chen W, Jang H, Smith DW, Akhras A, Tesfaye AA, Philip PA, Shields AF. Comparative analysis of different maintenance regimens after first-line induction in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 36: 789-789. DOI: 10.1200/Jco.2018.36.4_Suppl.789  0.383
2018 Barzi A, Salem ME, Xiu J, Korn WM, Marshall J, Shields AF, Lenz H. Differences in molecular profiles of males and females with colorectal cancer (CRC). Journal of Clinical Oncology. 36: 623-623. DOI: 10.1200/Jco.2018.36.4_Suppl.623  0.373
2018 Sinicrope FA, Shi Q, Hermitte F, Heying EN, Benson AB, Gill S, Goldberg R, Kahlenberg MS, Nair S, Shields AF, Sargent DJ, Galon J, Alberts SR. Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). Journal of Clinical Oncology. 36: 614-614. DOI: 10.1200/Jco.2018.36.4_Suppl.614  0.303
2018 Salem ME, Xiu J, Puccini A, Philip PA, Goldberg RM, Hwang JJ, Kc B, Korn WM, Shields AF, Lenz H, Marshall J. Molecular characterization of intestinal (IS) and diffuse subtypes (DS) of gastric adenocarcinomas. Journal of Clinical Oncology. 36: 60-60. DOI: 10.1200/Jco.2018.36.4_Suppl.60  0.33
2018 Ramanathan RK, McDonough S, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar JR, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery TE, Guthrie K, Hochster HS. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). Journal of Clinical Oncology. 36: 208-208. DOI: 10.1200/Jco.2018.36.4_Suppl.208  0.366
2018 Kamgar M, Dyson G, Diab M, Tesfaye AA, Korn WM, Shields AF, Philip PA. Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience. Journal of Clinical Oncology. 36: e16236-e16236. DOI: 10.1200/Jco.2018.36.15_Suppl.E16236  0.309
2018 Lum LG, Choi M, Le TM, Thakur A, Deol A, Ballen KK, Volodin L, Kindwall-Keller TL, Liu Q, Dyson G, Shields AF. Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody. Journal of Clinical Oncology. 36: 4108-4108. DOI: 10.1200/Jco.2018.36.15_Suppl.4108  0.311
2018 Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Puccini A, Naseem M, Battaglin F, Berger MD, Soni S, McSkane M, Barzi A, Zhang W, Hwang JJ, ... Shields AF, et al. Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC). Journal of Clinical Oncology. 36: 3611-3611. DOI: 10.1200/Jco.2018.36.15_Suppl.3611  0.342
2018 Shields AF, Ou F, Paul J, Sobrero AF, Yoshino T, Taieb J, Souglakos I, Shi Q, Kerr R, Labianca R, Yamanaka T, Vernerey D, Boukovinas I, Kato T, Torri V, et al. Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration. Journal of Clinical Oncology. 36: 3599-3599. DOI: 10.1200/Jco.2018.36.15_Suppl.3599  0.373
2018 Jagosky M, Goldberg RM, Raghavan D, Puccini A, Shields AF, Arguello D, Korn WM, Seeber A, Hwang JJ, Philip PA, Marshall J, Kim ES, Lenz H, Salem ME. Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC). Journal of Clinical Oncology. 36: 3577-3577. DOI: 10.1200/Jco.2018.36.15_Suppl.3577  0.355
2018 Wagner AJ, Tap WD, Shields AF, Patnaik A, Chugh R, Tinoco G, Michelson G, Alcantar O, Pelayo M, Zhang C, Severson P, Martin E, Trent JC. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 36: 11509-11509. DOI: 10.1200/Jco.2018.36.15_Suppl.11509  0.364
2018 LoRusso PM, Miller KD, Shields AF, Chung KY, Yoshisue K, Aoyama T, Lenz H. Abstract CT012: Phase I study of TAS-114 in combination with capecitabine in patients with advanced solid tumors Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct012  0.39
2018 Muqbil I, Mahdi Z, Choudhary R, Baloglu E, Senapedis W, Landesman Y, Shacham S, Kauffman M, Kim S, Beydoun R, Berri RN, Shields A, Mohammad RM, Azmi AS. Abstract 2491: Nuclear exporter protein XPO1 a novel prognostic and therapeutic target in gastric cancer Cancer Research. 78: 2491-2491. DOI: 10.1158/1538-7445.Am2018-2491  0.342
2017 Salem M, Lenz HJ, Shields A, Xiu J, Baker T, Hwang J, Philip P, Marshall J. Molecular variations between small bowel adenocarcinomas (SBAs), right-sided colon cancers (RT-Colon), and gastroesophageal cancers (GEC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii143-iii144. PMID 32135777 DOI: 10.1093/Annonc/Mdx262.017  0.352
2017 Sinicrope Frank A, Shi Q, Hermitte F, Heying E, Benson Al B, Gill S, Goldberg Richard M, Kahlenberg M, Nair S, Shields A, Sargent D, Galon J, Alberts Steven R. LBA-010Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28. PMID 30052792 DOI: 10.1093/Annonc/Mdx302.009  0.322
2017 Gareen IF, Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, Siegel B. Hospice Admission and Survival following 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29284672 DOI: 10.2967/Jnumed.117.205120  0.403
2017 Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, Gareen I, Siegel BA. Intended vs. Inferred Treatment after 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29191854 DOI: 10.2967/Jnumed.117.205047  0.373
2017 Blocker SJ, Douglas KA, Polin LA, Lee H, Hendriks BS, Lalo E, Chen W, Shields AF. Liposomal (64)Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts. Theranostics. 7: 4229-4239. PMID 29158822 DOI: 10.7150/Thno.21688  0.325
2017 Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 8: 86356-86368. PMID 29156800 DOI: 10.18632/Oncotarget.21169  0.404
2017 Shields AF, Jacobs P, Sznol M, Graham MM, Germain R, Lum L, Jaffee E, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung D, Wu AM, Sharon E, Shankar LK. Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28818991 DOI: 10.2967/Jnumed.117.195610  0.649
2017 Separovic D, Shields AF, Philip PA, Bielawski J, Bielawska A, Pierce JS, Tarca AL. Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study. Anticancer Research. 37: 1213-1218. PMID 28314284 DOI: 10.21873/Anticanres.11436  0.362
2017 Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, et al. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28298546 DOI: 10.1158/1078-0432.Ccr-16-3193  0.316
2017 Vaishampayan UN, Tehrani OS, Lawhorn-Crews JM, Heilbrun LK, Dobson K, Smith D, Dickow B, Shields AF. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [(18)F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28289967 DOI: 10.1007/S11307-017-1057-Y  0.366
2017 Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH. Preclinical Applications of 3'-Deoxy-3'-[(18)F]Fluorothymidine in Oncology - A Systematic Review. Theranostics. 7: 40-50. PMID 28042315 DOI: 10.7150/Thno.16676  0.345
2017 Weinberg BA, Lenz H, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Liu Z, Chen S, El Ghazaly H, Hwang JJ, Philip PA, Shields AF, Marshall J, Salem ME. Molecular characterization of squamous cell carcinoma of the anal canal (SCCA). Journal of Clinical Oncology. 35: 538-538. DOI: 10.1200/Jco.2017.35.4_Suppl.538  0.326
2017 Salem ME, Xiu J, Weinberg BA, El-Deiry WS, Weiner LM, Gatalica Z, Liu Z, El Ghazaly H, Xiao N, Hwang JJ, Philip PA, Shields AF, Lenz H, Marshall J. Characterization of tumor mutation burden (TMB) in gastrointestinal (GI) cancers. Journal of Clinical Oncology. 35: 530-530. DOI: 10.1200/Jco.2017.35.4_Suppl.530  0.398
2017 Marshall J, Lenz H, Xiu J, El-Deiry WS, Swensen J, El Ghazaly H, Gatalica Z, Hwang JJ, Philip PA, Shields AF, Salem ME. Molecular variances between rectal and left-sided colon cancers. Journal of Clinical Oncology. 35: 522-522. DOI: 10.1200/Jco.2017.35.4_Suppl.522  0.332
2017 Qureshi S, Xiu J, Sarraf Yazdy M, Shields AF, Philip PA, Marshall J, Lenz H, Salem ME. Molecular characterization of early vs. late onset gastroesophageal cancers. Journal of Clinical Oncology. 35: 46-46. DOI: 10.1200/Jco.2017.35.4_Suppl.46  0.314
2017 Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA, Bonnetain F, Watanabe T, Boukovinas I, Renfro LA, Grothey A, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Journal of Clinical Oncology. 35: LBA1-LBA1. DOI: 10.1200/Jco.2017.35.18_Suppl.Lba1  0.304
2017 Ismail H, Mohamed A, Song Y, Abdallah N, Surapaneni M, Kim S, Mandana K, Mettu J, Akhras A, Ahmed A, Philip PA, Shields AF, Tesfaye AA. Comparison of fluoropyrimidine based (FP)and taxane based platinum doublets (TP) in frontline treatment of patients with metastatic gastroesophageal adenocarcinomas (mGEAC): A retrospective analysis. Journal of Clinical Oncology. 35: e15604-e15604. DOI: 10.1200/Jco.2017.35.15_Suppl.E15604  0.388
2017 Song Y, Mohamed A, Ismail H, Abdallah N, Surapaneni M, Dyson G, Kamgar M, Akhras A, Mettu J, Ahmed A, Tesfaye AA, Philip PA, Shields AF. Comparative analysis of the effect of bevacizumab maintenance regimens after first-line chemotherapy in patients with metastatic colorectal cancer (MCRC): A single institution experience. Journal of Clinical Oncology. 35: e15032-e15032. DOI: 10.1200/Jco.2017.35.15_Suppl.E15032  0.411
2017 Newcomb PA, Sun W, Hua X, Banbury BL, Phipps AI, Kocarnik J, Harrison TA, Shi Q, Sinicrope FA, Thibodeau SN, Chan E, Gill S, Goldberg RM, Kahlenberg MS, Nair S, ... Shields AF, et al. Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance). Journal of Clinical Oncology. 35: 3604-3604. DOI: 10.1200/Jco.2017.35.15_Suppl.3604  0.325
2017 Salem ME, Lenz H, Xiu J, Hwang JJ, Philip PA, Shields AF, Marshall J. Colorectal cancer: Impact of primary tumor location on genetic alterations. Journal of Clinical Oncology. 35: 3578-3578. DOI: 10.1200/Jco.2017.35.15_Suppl.3578  0.321
2017 Salem ME, Xiu J, Lenz H, Atkins MB, Philip PA, Hwang JJ, Gatalica Z, Xiao N, Gibney GT, El-Deiry WS, Tan AR, Kim ES, Shields AF, Raghavan D, Marshall J. Characterization of tumor mutation load (TML) in solid tumors. Journal of Clinical Oncology. 35: 11517-11517. DOI: 10.1200/Jco.2017.35.15_Suppl.11517  0.393
2017 Grothey A, Sobrero A, Meyerhardt J, Yoshino T, Paul J, Taieb J, Souglakos I, Kerr R, Labianca R, Shields A, Bonnetain F, Yamanaka T, Boukovinas I, Shi Q, Meyers J, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) Annals of Oncology. 28: v613. DOI: 10.1093/Annonc/Mdx440.014  0.393
2016 Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). The Oncologist. PMID 27881709 DOI: 10.1634/Theoncologist.2016-0153  0.393
2016 McHugh CI, Lawhorn-Crews JM, Modi D, Douglas KA, Jones SK, Mangner TJ, Collins JM, Shields AF. Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: (18)F-FAU, (18)F-FMAU, and (18)F-FLT. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 16: 34. PMID 27751167 DOI: 10.1186/S40644-016-0092-2  0.341
2016 Subramaniam RM, Shields AF, Sachedina A, Hanna L, Duan F, Siegel BA, Hillner BE. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry. The Oncologist. PMID 27401896 DOI: 10.1634/Theoncologist.2015-0364  0.39
2016 Li J, Kim S, Shields AF, Douglas KA, McHugh CI, Lawhorn-Crews JM, Wu J, Mangner TJ, LoRusso PM. Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase. Journal of Clinical Pharmacology. PMID 27095537 DOI: 10.1002/Jcph.751  0.327
2016 Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR. Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147. International Journal of Cancer. PMID 27060850 DOI: 10.1002/Ijc.30135  0.335
2016 Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, et al. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26926685 DOI: 10.1200/Jco.2015.65.3949  0.323
2016 Vaishampayan UN, Podgorski I, Heilbrun LK, Smith DW, Lawhorn-Crews J, Dobson K, Fontana JA, Heath EI, Shields AF. Genomic and imaging biomarkers associated with cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 212-212. DOI: 10.1200/Jco.2016.34.2_Suppl.212  0.388
2016 Salem ME, Marshall J, Feldman R, Pishvaian MJ, El-Deiry WS, Hwang JJ, Lou E, Wang H, Gatalica Z, Reddy SK, Shields AF, Philip PA. Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases. Journal of Clinical Oncology. 34: 4121-4121. DOI: 10.1200/Jco.2016.34.15_Suppl.4121  0.359
2016 Salem ME, Xiu J, Khan SA, Wang H, Smaglo BG, El-Deiry WS, Hwang JJ, Pishvaian MJ, Lou E, Shields AF, Philip PA, Gatalica Z, Reddy SK, Marshall J. Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome. Journal of Clinical Oncology. 34: 4035-4035. DOI: 10.1200/Jco.2016.34.15_Suppl.4035  0.4
2016 Marshall J, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Pishvaian MJ, Philip PA, Reddy SK, Shields AF, Salem ME. Comparative molecular analyses of colon versus rectal tumors. Journal of Clinical Oncology. 34: 3552-3552. DOI: 10.1200/Jco.2016.34.15_Suppl.3552  0.371
2016 El-Deiry WS, Xiu J, Obeid E, Mehra R, Astsaturov IA, Wagner J, Lev A, Baumeister M, Shields AF, Salem ME, Hwang JJ, Vijayvergia N, Denlinger CS, Dotan E, Borghaei H, et al. Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1. Journal of Clinical Oncology. 34: 11604-11604. DOI: 10.1200/Jco.2016.34.15_Suppl.11604  0.341
2016 Bonomi RE, Popov V, Mangner T, Raz A, Shields AF, Gelovani JG. Abstract 4232: PET imaging of galectin-3 expression with [18F]FPDTG for detection of early breast carcinoma lesions in dense breast tissue Cancer Research. 76: 4232-4232. DOI: 10.1158/1538-7445.Am2016-4232  0.324
2016 Salem M, Philip P, Feldman R, Hwang J, Pishvaian M, Xiu J, Eldeiry W, Reddy S, Gatalica Z, Trivedi N, Zareb A, Colton B, Wang H, Shields A, Marshall J. Comparative molecular analyses of pancreatic cancer (PC): Younger vs. older patients (pts) Annals of Oncology. 27: vi210. DOI: 10.1093/Annonc/Mdw371.12  0.356
2015 Shaikh T, Zaki MA, Dominello MM, Handorf E, Konski AA, Cohen SJ, Shields A, Philip P, Meyer JE. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. Acta Oncologica (Stockholm, Sweden). 1-6. PMID 26581671 DOI: 10.3109/0284186X.2015.1110252  0.337
2015 Hamel LM, Chapman R, Malloy M, Eggly S, Penner LA, Shields AF, Simon MS, Klamerus JF, Schiffer C, Albrecht TL. Critical Shortage of African American Medical Oncologists in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26392105 DOI: 10.1200/Jco.2014.59.2493  0.319
2015 Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. Journal of the National Cancer Institute. 107. PMID 26374429 DOI: 10.1093/Jnci/Djv248  0.357
2015 Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA, et al. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 1681-9. PMID 26359256 DOI: 10.2967/Jnumed.115.160663  0.369
2015 Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigan DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA. Repeatability of 18F-FDG PET/CT in Advanced Non-small Cell Lung Cancer: Prospective Assessment in Two Multicenter Trials. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 25908829 DOI: 10.2967/Jnumed.114.147728  0.361
2015 Hillner BE, Siegel BA, Hanna L, Duan F, Quinn B, Shields AF. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 222-8. PMID 25593113 DOI: 10.2967/Jnumed.114.150391  0.408
2015 Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA. PET scans as a predictive marker of survival in advanced colorectal cancer. Clinical Colorectal Cancer. 14: 35-40. PMID 25481195 DOI: 10.1016/J.Clcc.2014.10.001  0.419
2015 Choi M, Dyson G, Thakur A, Mahaseth H, Philip PA, Shields AF, Deol A, Lum LG. Phase I study of anti-CD3 x anti-EGFR–armed activated T-cells for treatment of advanced colorectal or pancreatic cancer. Journal of Clinical Oncology. 33: 698-698. DOI: 10.1200/Jco.2015.33.3_Suppl.698  0.417
2015 Isakoff SJ, Saleh MN, Lugovskoy A, Mathews S, Czibere AG, Shields AF, Bahleda R, Soria J, Arnedos M. First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3. Journal of Clinical Oncology. 33: 384-384. DOI: 10.1200/Jco.2015.33.3_Suppl.384  0.33
2015 Saeed Tehrani O, Vaishampayan UN, Lawhorn-Crews J, Heilbrun LK, Dobson K, Smith DW, Dickow B, Shields AF. Impact of zoledronate on FMAU positron emission tomography (PET) scanning results in metastatic prostate cancer. Journal of Clinical Oncology. 33: e16069-e16069. DOI: 10.1200/Jco.2015.33.15_Suppl.E16069  0.366
2015 Wilcox RE, Shi Q, Sinicrope FA, Sargent DJ, Foster NR, Meyers JP, Goldberg RM, Nair S, Shields AF, Chan E, Gill S, Kahlenberg MS, Alberts SR. Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147). Journal of Clinical Oncology. 33: 3590-3590. DOI: 10.1200/Jco.2015.33.15_Suppl.3590  0.356
2015 Singh PP, Shi Q, Foster NR, Grothey A, Nair S, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance). Journal of Clinical Oncology. 33: 3531-3531. DOI: 10.1200/Jco.2015.33.15_Suppl.3531  0.355
2015 Miller K, LoRusso PM, Munster P, Krop I, Ma C, Lee H, Reynolds J, Campbell K, Moyo V, Hendriks B, Wickham T, Siegel BA, Shields AF. Abstract P4-15-04: Effect of pre-treatment with cyclophosphamide on MM-302 (HER2-targeted liposomal doxorubicin) deposition in HER2-positive metastatic breast cancer patients assessed by64Cu-MM-302 PET/CT Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-15-04  0.384
2015 Lugovskoy AA, Curley M, Baum J, Adams S, Iadevaia S, Rimkunas V, Camblin A, Nie L, Tan G, Johnson B, Mathews S, Horgan K, Louis CU, Czibere AG, Arnedos M, ... ... Shields A, et al. Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct237  0.369
2015 LoRusso P, Krop I, Miller K, Ma C, Siegel BA, Shields AF, Molnar I, Wickham T, Reynolds J, Campbell K, Hendriks B, McClure T, Moyo V, Munster P. Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct234  0.376
2015 Munster P, Eckhardt SG, Patnaik A, Shields AF, Tolcher AW, Davis SL, Heymach JV, Xu L, Kapoun AM, Faoro L, Dupont J, Ferrarotto R. Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C42  0.418
2014 Sargent DJ, Paul J, Sobrero A, André T, Shields AF, Yoshino T, Souglakos I, Iveson T, Labianca R, Taieb J, Meyerhardt J, Ohtsu A, Grothey A. 609TiPTHE IDEA (INTERNATIONAL DURATION EVALUATION OF ADJUVANT CHEMOTHERAPY) COLLABORATION: A PROSPECTIVE POOLED NON-INFERIORITY ANALYSIS OF > 11,500 PATIENTS FROM 6 PHASE III TRIALS OF ADJUVANT THERAPY DURATION WITH FOLFOX (FOLFOX4 OR MFOLFOX6) OR XELOX (3 VS. 6 MONTHS) FOR STAGE III COLON CANCER. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv207-iv208. PMID 28171909 DOI: 10.1093/Annonc/Mdu333.110  0.358
2014 Mahaseth H, Maity SN, Gabrail NY, Mahipal A, Gericitano JF, Shacham S, Rashal T, Klebanov B, Carlson R, Shacham E, Vincent D, Kauffman M, Shields AF, Mirza MR, Araujo JC. 758OSELINEXOR (KPT-330), AN ORAL, SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SHOWS ANTI-PROSTATE CANCER (PRCA) ACTIVITY PRECLINICALLY & DISEASE CONTROL IN PATIENTS (PTS) WITH CHEMOTHERAPY REFRACTORY, CASTRATE-RESISTANT PROSTATE CANCER (CRPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv257. PMID 28170586 DOI: 10.1093/Annonc/Mdu336.6  0.364
2014 Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 113: 35-40. PMID 25441058 DOI: 10.1016/J.Radonc.2014.08.014  0.372
2014 Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Quinn B, Coleman RE. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1054-61. PMID 24819422 DOI: 10.2967/Jnumed.113.135475  0.397
2014 O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1927-34. PMID 24799484 DOI: 10.1200/Jco.2013.53.7753  0.358
2014 Patki M, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M. Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 519-526. PMID 24736075 DOI: 10.1097/Jto.0000000000000111  0.319
2014 Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Coleman RE. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 574-81. PMID 24578240 DOI: 10.2967/Jnumed.113.130005  0.364
2014 Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, et al. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clinical Colorectal Cancer. 13: 100-9. PMID 24512953 DOI: 10.1016/J.Clcc.2013.12.002  0.378
2014 Mahaseth H, Shields AF. Maintenance treatment for metastatic colorectal cancer Colorectal Cancer. 3: 501-509. DOI: 10.2217/Crc.14.39  0.394
2014 Mau-Soerensen M, Razak ARA, Mahipal A, Mahaseth H, Gerecitano JF, Shacham S, Yau CYF, Lassen U, Shields AF, McCauley D, Cooksey J, Tan DSP, Rashal T, Shacham E, Landesman Y, et al. Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort. Journal of Clinical Oncology. 32: 482-482. DOI: 10.1200/Jco.2014.32.3_Suppl.482  0.368
2014 Kollepara SLS, Choi M, Heilbrun LK, Smith DW, Shields AF, Philip PA. PET scan as a prognostic marker in advanced colorectal cancer. Journal of Clinical Oncology. 32: 442-442. DOI: 10.1200/Jco.2014.32.3_Suppl.442  0.42
2014 Salem ME, Al-hajeili MR, Dyson G, Stanski N, Jain T, Mahaseth H, Choi M, Shields AF, Philip PA. Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma. Journal of Clinical Oncology. 32: 192-192. DOI: 10.1200/Jco.2014.32.3_Suppl.192  0.365
2014 Salem ME, Alistar AT, Dyson G, Stanski N, Mahaseth H, Choi M, Shields AF, Philip PA. Albumin-bound paclitaxel plus gemcitabine after first-line FOLFIRINOX therapy in patients with pancreatic cancer. Journal of Clinical Oncology. 32: e15252-e15252. DOI: 10.1200/Jco.2014.32.15_Suppl.E15252  0.382
2014 Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Pryma DA, Specht JM, Hovanessian Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA. Phase II study of 3'-deoxy-3'-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locally advanced breast cancer (LABC): Preliminary results of ACRIN 6688. Journal of Clinical Oncology. 32: 526-526. DOI: 10.1200/Jco.2014.32.15_Suppl.526  0.377
2014 Jagtap DB, Thakur A, Deol A, Al-Kadhimi Z, Simon MS, Flaherty LE, Shields AF, Schalk D, Paul E, Kondadasula V, Liu Q, Lum LG. Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients. Journal of Clinical Oncology. 32: 3073-3073. DOI: 10.1200/Jco.2014.32.15_Suppl.3073  0.36
2014 Hendriks B, Shields A, Siegel B, Miller K, Munster P, Ma C, Campbell K, Moyo V, Wickham T, LoRusso P. PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients Annals of Oncology. 25: i19. DOI: 10.1093/Annonc/Mdu068.1  0.324
2014 Zaki M, Shaikh T, Dominello M, McSpadden E, Yu M, Cohen S, Scott W, Shields A, Philip P, Choi M, Meyer J, Konski A. PET SUVmax as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy in Patients With Carcinoma of the Esophagus International Journal of Radiation Oncology*Biology*Physics. 90: S350-S351. DOI: 10.1016/J.Ijrobp.2014.05.1143  0.333
2014 Dominello M, Shaikh T, Zaki M, Zamen O, Hurst N, Martin J, McSpadden E, Shields A, Phillip P, Meyer J, Konski A. Does Taxane-based Chemoradiation therapy Increase the Risk of Pneumonitis in the Treatment of Locally Advanced Esophageal Cancer? International Journal of Radiation Oncology*Biology*Physics. 90: S12-S13. DOI: 10.1016/J.Ijrobp.2014.05.094  0.323
2013 Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA. Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. Isrn Oncology. 2013: 538376. PMID 24167742 DOI: 10.1155/2013/538376  0.341
2013 André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports. 9: 261-269. PMID 24032000 DOI: 10.1007/S11888-013-0181-6  0.386
2013 Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 903-12. PMID 23674576 DOI: 10.2967/Jnumed.112.112201  0.376
2013 Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 119: 285-92. PMID 22786786 DOI: 10.1002/Cncr.27734  0.361
2013 Salem ME, Arun M, Dyson G, Saad C, Arbabi C, Jain T, Taylor S, Kunz S, Choi M, Shields AF, Philip PA. Characteristics of colorectal cancer in patients younger than 40 years compared to older patients. Journal of Clinical Oncology. 31: 371-371. DOI: 10.1200/Jco.2013.31.4_Suppl.371  0.366
2013 Tan J, Choi M, Philip PA, Dyson G, Shields AF, Kim RD. The outcome of patients with advanced hepatocellular carcinoma (HCC) in pre- and post-sorafenib eras using the SEER database. Journal of Clinical Oncology. 31: 276-276. DOI: 10.1200/Jco.2013.31.4_Suppl.276  0.321
2013 Konski AA, Meyer JE, Philip PA, Shields AF, Hall MJ, Choi M, Duncan G, Adaire B, McSpadden E, Cohen SJ. A phase I study of hyperfractionated low-dose radiotherapy (RT) as a chemotherapy sensitizer in combination with gemcitabine (G) and erlobtinib (E) in advanced pancreatic cancer. Journal of Clinical Oncology. 31: 268-268. DOI: 10.1200/Jco.2013.31.4_Suppl.268  0.335
2013 Konski A, Meyer J, Philip P, Shields A, Hall M, Choi M, Duncan G, Adaire B, McSpadden E, Cohen S. Preliminary Results of a Phase 1 Study of Hyperfractionated Low-Dose Radiation Therapy (RT) as a Chemotherapy Sensitizer in Combination With Gemcitabine (G) and Erlotinib (E) in Advanced Pancreatic Cancer International Journal of Radiation Oncology*Biology*Physics. 87: S311. DOI: 10.1016/J.Ijrobp.2013.06.816  0.354
2012 Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. Jama. 307: 1383-93. PMID 22474202 DOI: 10.1001/Jama.2012.385  0.41
2012 Hillner BE, Siegel BA, Hanna L, Shields AF, Duan F, Gareen IF, Quinn B, Coleman RE. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 831-7. PMID 22448033 DOI: 10.2967/Jnumed.112.103911  0.422
2012 Shields AF. PET imaging of tumor growth: not as easy as it looks. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1189-91. PMID 22275505 DOI: 10.1158/1078-0432.Ccr-11-3198  0.347
2012 Goncalves PH, Ruch JM, Byer J, Shields AF, Choi M, Kim RD, Zalupski MM, Philip PA. Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with pancreatic cancer (PCA). Journal of Clinical Oncology. 30: e14519-e14519. DOI: 10.1200/Jco.2012.30.15_Suppl.E14519  0.415
2012 Osuorji I, Dyson G, Yerasuri D, Philip PA, Shields AF, Choi M. Prognostic factors for metastatic colorectal cancer with and without bevacizumab therapy. Journal of Clinical Oncology. 30: e14163-e14163. DOI: 10.1200/Jco.2012.30.15_Suppl.E14163  0.35
2012 Salem M, Jain N, Taylor S, Dyson G, Beebe-Dimmer J, Le IP, Choi M, Shields AF, Critchfield JJ, Philip PA. Radiographic Parameters in Predicting Outcome of Patients with Hepatocellular Carcinoma (HCC) Treated with YTTRIUM-90 Microsphere Radioembolization (SIRT) Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33315-9  0.348
2011 Sloan JA, Mahoney MR, Sargent DJ, Hubbard JM, Liu H, Basch EM, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Alberts SR. Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6122. PMID 28022499 DOI: 10.1200/Jco.2011.29.15_Suppl.6122  0.365
2011 Choi M, Dyson G, Philip PA, Shields AF. Clinical outcome of advanced colorectal cancer patients pre- and post-bevacizumab therapy using the SEER database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6083. PMID 28021752 DOI: 10.1200/Jco.2011.29.15_Suppl.6083  0.413
2011 Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Nair SG. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3607. PMID 28020864 DOI: 10.1200/Jco.2011.29.15_Suppl.3607  0.389
2011 Bauer TM, Bekaii-Saab TS, Li X, Villalona-Calero MA, Philip PA, Shields AF, Zalupski MM, Hammad N, El-Rayes BF. CA19-9 for the prediction of efficacy of chemotherapy in patients with advanced pancreas cancer: A pooled analysis of six prospective trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4071. PMID 28020465 DOI: 10.1200/Jco.2011.29.15_Suppl.4071  0.339
2011 Roh MS, Yothers GA, O'Connell MJ, Beart RW, Pitot HC, Shields AF, Parda DS, Sharif S, Allegra CJ, Petrelli NJ, Landry JC, Ryan DP, Arora A, Evans TL, Soori GS, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3503. PMID 28020345 DOI: 10.1200/Jco.2011.29.15_Suppl.3503  0.325
2011 Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Sinicrope F, Nair SG, Alberts SR. Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3522. PMID 28020320 DOI: 10.1200/Jco.2011.29.15_Suppl.3522  0.409
2011 Mahoney MR, Sloan JA, Hubbard JM, Liu H, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Nair SG, Sargent DJ, Alberts SR. Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3541. PMID 28020301 DOI: 10.1200/Jco.2011.29.15_Suppl.3541  0.363
2011 Paximadis P, Elliott D, Shields AF, Philip PA, Weaver DW, Konski AA. High linear energy transfer (LET) radiation therapy in recurrent, metastatic, or unresectable rectal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 612. PMID 27985965 DOI: 10.1200/Jco.2011.29.4_Suppl.612  0.307
2011 Christensen ME, Paximadis P, Shields AF, Philip PA, Weaver DW, Konski AA. Mixed photon and neutron radiotherapy given concurrently with chemotherapy in unresectable pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 328. PMID 27985889 DOI: 10.1200/Jco.2011.29.4_Suppl.328  0.394
2011 Hillner BE, Siegel BA, Shields AF, Duan F, Gareen IF, Hanna L, Coleman RE. Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 13: 161-5. PMID 21080232 DOI: 10.1007/S11307-010-0427-5  0.322
2011 El-Rayes BF, Jasti P, Severson RK, Almhanna K, Philip PA, Shields A, Zalupski M, Heilbrun LK. Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials. Pancreas. 39: 967-71. PMID 20467351 DOI: 10.1097/Mpa.0B013E3181Da91Dd  0.371
2011 El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Investigational New Drugs. 29: 694-9. PMID 20107864 DOI: 10.1007/S10637-010-9386-6  0.402
2011 Azmi AS, Philip PA, Choi M, Shields AF, Sarkar FH, Mohammad RM. Abstract 4910: Unveiling the role of network and systems biology in pancreatic cancer drug discovery Cancer Research. 71: 4910-4910. DOI: 10.1158/1538-7445.Am2011-4910  0.351
2010 Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: CRA3507. PMID 27937468 DOI: 10.1200/Jco.2010.28.18_Suppl.Cra3507  0.375
2010 Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R, El-Rayes BF. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia-Pacific Journal of Clinical Oncology. 6: 98-105. PMID 20565421 DOI: 10.1111/J.1743-7563.2010.01290.X  0.356
2010 El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 1999-2004. PMID 20332133 DOI: 10.1093/Annonc/Mdq065  0.353
2010 Gupta S, Parsa V, Adsay V, Heilbrun LK, Smith D, Shields AF, Weaver D, Philip PA, El-Rayes BF. Clinicopathological analysis of primary epithelial appendiceal neoplasms. Medical Oncology (Northwood, London, England). 27: 1073-8. PMID 19851895 DOI: 10.1007/S12032-009-9337-2  0.353
2010 Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields AF. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. American Journal of Clinical Oncology. 33: 257-61. PMID 19806035 DOI: 10.1097/Coc.0B013E3181A76A0B  0.439
2010 Gupta S, Heilbrun LK, Smith D, Shields AF, Philip PA. 18f-fluorodeoxyglucose-positron emission tomography (FDG-PET) as a predictive biomarker in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 28: e14120-e14120. DOI: 10.1200/Jco.2010.28.15_Suppl.E14120  0.361
2010 Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shields AF, Chan E, Gill S, Kahlenberg MS, Nair S, Alberts SR. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. Journal of Clinical Oncology. 28: 3508-3508. DOI: 10.1200/Jco.2010.28.15_Suppl.3508  0.34
2009 Philip PA, Gupta S, Heilbrun L, Smith D, El-Rayes B, Shields A. (18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15037. PMID 27964469 DOI: 10.1200/Jco.2009.27.15_Suppl.E15037  0.364
2009 El-Rayes BF, Patel B, Zalupski M, Hammad N, Shields A, Heilbrun L, Venkatramanamoorthy R, Philip P. A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4563. PMID 27963057 DOI: 10.1200/Jco.2009.27.15_Suppl.4563  0.337
2009 Mobayed M, Heilbrun LK, Shields AF, Washington T, Venkatramanamoorthy R, Philip PA, El-Rayes BF. Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer. Case Reports in Oncology. 2: 220-228. PMID 20737041 DOI: 10.1159/000250082  0.389
2009 Nimmagadda S, Mangner TJ, Lawhorn-Crews JM, Haberkorn U, Shields AF. Herpes simplex virus thymidine kinase imaging in mice with (1-(2'-deoxy-2'-[18F]fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) and metabolite (1-(2'-deoxy-2'-[18F]fluoro-1-β-D-arabinofuranosyl)-5-uracil). European Journal of Nuclear Medicine and Molecular Imaging. 36: 1987-93. PMID 19506865 DOI: 10.1007/S00259-009-1177-Y  0.619
2009 Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hanna L, Stine SH, Coleman RE. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer. 115: 410-8. PMID 19016303 DOI: 10.1002/Cncr.24000  0.384
2009 Hillner BE, Siegel B, Shields AF, Liu D, Gareen IF, Hanna L, Stine SH, Coleman RE. Erratum: The impact of Positron Emission Tomography (PET) on expected management during cancer treatment (Cancer (2009) 115 (410-8)) Cancer. 115. DOI: 10.1002/Cncr.24195  0.361
2008 Hammad N, Philip PA, Shields AF, Sarkar FH, Abruzzese JL, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, El-Rayes BF. A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 15540. PMID 27947415 DOI: 10.1200/Jco.2008.26.15_Suppl.15540  0.362
2008 Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1928-35. PMID 18997054 DOI: 10.2967/Jnumed.108.056713  0.367
2008 Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, Mangner TJ, Heilbrun LK, Muzik O. Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4463-8. PMID 18628460 DOI: 10.1158/1078-0432.Ccr-07-5243  0.383
2008 Nimmagadda S, Shields AF. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Reviews. 27: 575-87. PMID 18512023 DOI: 10.1007/s10555-008-9148-5  0.591
2008 Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2155-61. PMID 18362365 DOI: 10.1200/Jco.2007.14.5631  0.368
2008 Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, ... Shields AF, et al. Recommendations on the use of 18F-FDG PET in oncology. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 480-508. PMID 18287273 DOI: 10.2967/Jnumed.107.047787  0.396
2008 El-Rayes BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF, Philip PA. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 61: 283-9. PMID 17429629 DOI: 10.1007/S00280-007-0472-1  0.402
2008 Jasti P, El-Rayes BF, Heilbrun LK, Philip PA, Zalupski MM, Shields AF, Venkatramanamoorthy R, Severson R. A comparison of advanced pancreatic cancer patients treated on clinical trials with those from a SEER registry over an 18 year period Journal of Clinical Oncology. 26: 4628-4628. DOI: 10.1200/Jco.2008.26.15_Suppl.4628  0.387
2008 El-Rayes BF, Hammad N, Philip PA, Shields AF, Heilbrun LK. A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer Journal of Clinical Oncology. 26: 15608-15608. DOI: 10.1200/Jco.2008.26.15_Suppl.15608  0.366
2007 Hillner BE, Liu D, Coleman RE, Shields AF, Gareen IF, Hanna L, Stine SH, Siegel BA. The National Oncologic PET Registry (NOPR): design and analysis plan. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1901-8. PMID 17942807 DOI: 10.2967/Jnumed.107.043687  0.379
2007 Tehrani OS, Muzik O, Heilbrun LK, Douglas KA, Lawhorn-Crews JM, Sun H, Mangner TJ, Shields AF. Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1436-41. PMID 17785728 DOI: 10.2967/Jnumed.107.042762  0.333
2007 Nimmagadda S, Mangner TJ, Douglas KA, Muzik O, Shields AF. Biodistribution, PET, and radiation dosimetry estimates of HSV-tk gene expression imaging agent 1-(2'-Deoxy-2'-18F-Fluoro-beta-D-arabinofuranosyl)-5-iodouracil in normal dogs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 655-60. PMID 17401105 DOI: 10.2967/Jnumed.106.036830  0.616
2007 Lindsay MJ, Siegel BA, Tunis SR, Hillner BE, Shields AF, Carey BP, Coleman RE. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development. Ajr. American Journal of Roentgenology. 188: 1109-13. PMID 17377055 DOI: 10.2214/Ajr.06.1175  0.347
2007 Shields AF, Heath E, DeLuca P, Pilat M, Wozniak A, Gadgeel S, Puchalski T, Xu J, Liu Q, LoRusso P. AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study Journal of Clinical Oncology. 25: 3544-3544. DOI: 10.1200/Jco.2007.25.18_Suppl.3544  0.351
2007 Mobayed M, Philip PA, Shields AF, Heilbrun L, Washington T, Vaishampayan U, Venkatramanamoorthy R, El-Rayes BF. Activity and safety of carboplatin and paclitaxel followed by capecitabine and radiation as adjuvant therapy for gastric cancer (GC) Journal of Clinical Oncology. 25: 15162-15162. DOI: 10.1200/Jco.2007.25.18_Suppl.15162  0.382
2006 Sun H, Collins JM, Mangner TJ, Muzik O, Shields AF. Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studies. Cancer Chemotherapy and Pharmacology. 57: 343-8. PMID 16001172 DOI: 10.1007/S00280-005-0037-0  0.37
2006 El-Rayes BF, Shields AF, Vaishampayan U, Heilbrun LK, Zalupski MM, Philip PA. A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer Journal of Clinical Oncology. 24: 3584-3584. DOI: 10.1200/Jco.2006.24.18_Suppl.3584  0.407
2006 Lorusso PM, Heath E, Valdivieso M, Pilat M, Wozniak A, Gadgeel S, Shields A, Puchalski T, Ewesuedo R. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors Journal of Clinical Oncology. 24: 3034-3034. DOI: 10.1200/Jco.2006.24.18_Suppl.3034  0.34
2005 Nimmagadda S, Mangner TJ, Sun H, Klecker RW, Muzik O, Lawhorn-Crews JM, Douglas KA, Collins JM, Shields AF. Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1916-22. PMID 16269607  0.582
2005 Leichman CG, Benedetti JK, Zalupski MM, Hochster H, Shields AF, Lenz HJ, Wade Iii JL, Bearden Iii JD, Macdonald JS. Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. Clinical Colorectal Cancer. 5: 119-23. PMID 16098253 DOI: 10.3816/Ccc.2005.N.024  0.37
2005 El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Adsay V, Philip PA. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Investigational New Drugs. 23: 583-90. PMID 16034525 DOI: 10.1007/S10637-005-1028-Z  0.417
2005 Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, Mangner TJ, Heilbrun LK, Muzik O. A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention. European Journal of Nuclear Medicine and Molecular Imaging. 32: 1269-75. PMID 15991018 DOI: 10.1007/S00259-005-1813-0  0.325
2005 El-Rayes BF, Shields AF, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. American Journal of Clinical Oncology. 28: 152-6. PMID 15803009 DOI: 10.1097/01.Coc.0000142590.70472.E2  0.339
2005 Megyeri A, Bacsó Z, Shields A, Eliason JF. Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 64: 62-71. PMID 15729713 DOI: 10.1002/Cyto.A.20121  0.313
2005 El-Rayes BF, Ibrahim D, Shields AF, LoRusso PM, Zalupski MM, Philip PA. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Investigational New Drugs. 23: 57-62. PMID 15528981 DOI: 10.1023/B:Drug.0000047106.20104.A7  0.309
2005 Patel B, Heilburn L, Khanna A, Venkatramanamoorthy R, Shields A, Philip P, Zalupski M, El-Rayes B. CA 19–9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy Journal of Clinical Oncology. 23: 4189-4189. DOI: 10.1200/Jco.2007.25.18_Suppl.15094  0.368
2005 El-Rayes BF, Zalupski MM, Shields AF, Heilbrun LK, Bekaii-Saab T, Vaishampayan U, Philip PA. A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer Journal of Clinical Oncology. 23: 3677-3677. DOI: 10.1200/Jco.2005.23.16_Suppl.3677  0.395
2004 El-Rayes BF, Shields AF, Vaishampayan U, Heilbrun L, Bekaii-Saab T, Zalupski MM, Philip PA. Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3766. PMID 28014138 DOI: 10.1200/Jco.2004.22.14_Suppl.3766  0.368
2004 El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris A, Philip PA. A phase II study of carboplatin and paclitaxel in esophageal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 15: 960-5. PMID 15151955 DOI: 10.1093/Annonc/Mdh230  0.395
2004 Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer International Journal of Radiation Oncology Biology Physics. 59: 454-459. PMID 15145162 DOI: 10.1016/J.Ijrobp.2003.11.019  0.317
2004 Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 100: 531-7. PMID 14745869 DOI: 10.1002/Cncr.11925  0.347
2004 Kobrossy B, El-Rayes BF, Shields AF, Vaishampayan U, Heilbrun L, Zalupski MM, Philip PA. A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer Journal of Clinical Oncology. 22: 4120-4120. DOI: 10.1200/Jco.2004.22.90140.4120  0.369
2003 Al-Sukhun S, Zalupski MM, Ben-Josef E, Vaitkevicius VK, Philip PA, Soulen R, Weaver D, Adsay V, Heilbrun LK, Levin K, Forman JD, Shields AF. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. American Journal of Clinical Oncology. 26: 543-9. PMID 14663369 DOI: 10.1097/01.Coc.0000037143.60502.54  0.393
2003 El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2920-5. PMID 12885810 DOI: 10.1200/Jco.2003.03.022  0.381
2003 Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1498-504. PMID 12697873 DOI: 10.1200/Jco.2003.09.114  0.41
2003 el-Rayes BF, Shields AF, Vaitkevicius V, Philip PA. Developments in the systemic therapy of pancreatic cancer. Cancer Investigation. 21: 73-86. PMID 12643012 DOI: 10.1081/Cnv-120016406  0.412
2003 Chander S, Lay Ergun E, Shields AF. An FDG positron emission tomographic study in a case of gastrointestinal stromal tumor. Clinical Nuclear Medicine. 28: 327-9. PMID 12642718 DOI: 10.1097/01.Rlu.0000057616.90111.E0  0.365
2003 Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. American Journal of Clinical Oncology. 26: 37-41. PMID 12576922 DOI: 10.1097/00000421-200302000-00008  0.4
2003 Sun H, Collins JM, Mangner TJ, Muzik O, Shields AF. Imaging [18F]FAU [1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil] in dogs. Nuclear Medicine and Biology. 30: 25-30. PMID 12493539 DOI: 10.1016/S0969-8051(02)00376-1  0.303
2002 Chander S, Ergun EL, Chugani HT, Chugani DC, Juhasz C, Shields AF, Weaver DW. High 2-deoxy-2-[18F]fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 4: 363-8. PMID 14537112 DOI: 10.1016/S1536-1632(02)00021-5  0.348
2002 LoRusso PM, Prakash S, Wozniak A, Flaherty L, Zalupski M, Shields A, Sands H, Parchment R, Jasti B. Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU). Investigational New Drugs. 20: 63-71. PMID 12003195 DOI: 10.1023/A:1014430216434  0.334
2001 Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. American Journal of Clinical Oncology. 24: 447-52. PMID 11586094 DOI: 10.1097/00000421-200110000-00007  0.389
2001 Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 92: 569-77. PMID 11505401 DOI: 10.1002/1097-0142(20010801)92:3<569::Aid-Cncr1356>3.0.Co;2-D  0.362
2001 Shields AF, Lange LM, Zalupski MM. Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. American Journal of Clinical Oncology. 24: 96-8. PMID 11232960 DOI: 10.1097/00000421-200102000-00019  0.411
2000 Ahmed S, Vaitkevicius VK, Zalupski MM, Du W, Arlauskas P, Gordon C, Kellogg C, Shields AF. Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study. American Journal of Clinical Oncology. 23: 420-4. PMID 10955876 DOI: 10.1097/00000421-200008000-00022  0.325
2000 Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia (New York, N.Y.). 2: 71-88. PMID 10933070 DOI: 10.1038/Sj.Neo.7900075  0.351
1999 Shields AF, Philip PA, LoRusso PM, Ferris AM, Zalupski MM. Phase II study of CI-958 in colorectal cancer. Cancer Chemotherapy and Pharmacology. 43: 162-4. PMID 9923823 DOI: 10.1007/S002800050878  0.369
1998 Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investigational New Drugs. 16: 93-6. PMID 9740550 DOI: 10.1023/A:1006087114621  0.379
1998 Mohammad RM, Dugan MC, Mohamed AN, Almatchy VP, Flake TM, Dergham ST, Shields AF, Al-Katib AA, Vaitkevicius VK, Sarkar FH. Establishment of a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents Pancreas. 16: 19-25. PMID 9436858 DOI: 10.1097/00006676-199801000-00004  0.337
1997 Zalupski MM, Philip PA, LoRusso P, Shields AF. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemotherapy and Pharmacology. 40: 225-7. PMID 9219505 DOI: 10.1007/S002800050650  0.384
Show low-probability matches.